Haw Par Corporation Ltd
SGX:H02

Watchlist Manager
Haw Par Corporation Ltd Logo
Haw Par Corporation Ltd
SGX:H02
Watchlist
Price: 11.15 SGD -0.18% Market Closed
Market Cap: 2.5B SGD
Have any thoughts about
Haw Par Corporation Ltd?
Write Note

Relative Value

The Relative Value of one H02 stock under the Base Case scenario is 7.22 SGD. Compared to the current market price of 11.15 SGD, Haw Par Corporation Ltd is Overvalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

H02 Relative Value
Base Case
7.22 SGD
Overvaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
73
vs Industry
15
Median 3Y
11.5
Median 5Y
11.2
Industry
2.6
vs History
80
vs Industry
36
Median 3Y
14.1
Median 5Y
13.9
Industry
23
vs History
61
vs Industry
11
Median 3Y
51
Median 5Y
51
Industry
17.8
vs History
79
vs Industry
13
Median 3Y
55.3
Median 5Y
56.2
Industry
25.4
vs History
53
vs Industry
71
Median 3Y
0.6
Median 5Y
0.7
Industry
2.2
vs History
65
vs Industry
17
Median 3Y
9.8
Median 5Y
9.6
Industry
2.8
vs History
66
vs Industry
15
Median 3Y
17.7
Median 5Y
17.4
Industry
5.4
vs History
57
vs Industry
14
Median 3Y
35.4
Median 5Y
33.4
Industry
13.7
vs History
58
vs Industry
16
Median 3Y
39.9
Median 5Y
37.1
Industry
17.2
vs History
61
vs Industry
16
Median 3Y
43.5
Median 5Y
43.5
Industry
16.5
vs History
61
vs Industry
14
Median 3Y
83.3
Median 5Y
82
Industry
19.3
vs History
58
vs Industry
72
Median 3Y
0.6
Median 5Y
0.7
Industry
2

Multiples Across Competitors

H02 Competitors Multiples
Haw Par Corporation Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
Haw Par Corporation Ltd
SGX:H02
2.5B SGD 10.3 10.5 26.7 29.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
761.8B USD 18.5 90.9 48.9 54.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
368.4B USD 4.2 25 12.1 15.8
US
Merck & Co Inc
NYSE:MRK
250.9B USD 4 20.6 10.4 12.5
CH
Roche Holding AG
SIX:ROG
208.8B CHF 3.6 18.2 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.2B CHF 4.2 12.6 10 14.9
UK
AstraZeneca PLC
LSE:AZN
158.6B GBP 4.1 31.3 169.3 253.7
IE
Endo International PLC
LSE:0Y5F
155B USD 66.9 -53 248.3 622.6
P/E Multiple
Earnings Growth
SG
Haw Par Corporation Ltd
SGX:H02
Average P/E: 30.5
10.5
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
90.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25
-22%
US
Merck & Co Inc
NYSE:MRK
20.6
7 336%
CH
Roche Holding AG
SIX:ROG
18.2
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.3
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -53 N/A

See Also

Discover More
Back to Top